Whether such a mechanism is behind the observed movement towards mesenchymal phenotypes in carcinoma tumor tissues after talazoparib treatment or whether the drug preferential kills more sensitive epithelial tumor cells and thereby selects for more inherently resistant vimentin-positive mesenchymal phenotype cells unfortunately cannot be determined by the assay used this study. The gene discussed is VIM; the disease is neoplasm.